Objective:To compare the ef icacy and safety of Lobaplatin plus Etoposide (EL) and Cisplatin plus Etoposide (EP) regimens in chemonaive with extensive-stage smal-cel lung cancer (SCLC). Methods:Between July 2010 and July 2011, a total of 62 patients with extensive-stage smal-cel lung cancer who received initial treatment in our hospital and 309 hospital of PLA. 31 patients were randomly assigned to the EL Group:Lobaplatin was given intravenously at a dose of 30 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1 to 3 of 21-day cycles for a maximum of six cycles. Another 31 patients were assigned to the EP Group:Cisplatin was given intravenously at a dose of 75 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1 to 3 of 21-day cycles for a maximum of six cycles. We evaluated the ef icacy, overal response rate (ORR), disease control rate (DCR), the progression-free survival (PFS) and toxicity between the patients of the two groups. Results:Al 62 patients were eligible. In the EL group, 2 (6.5%) patients had complete response, 20 (64.5%) patients had partial response, 5 (16.1%) patients had stable disease and 4 (12.9%) patients had progress disease. In the EP group, 2 (6.5%) patients had complete response, 22 (70.9%) patients had partial response, 4 (12.9%) patients had stable disease and 3 (9.7%) patients had progress disease. The ORR of EL and EP group were 70.9%and 77.4%, respectively, showing no significant dif erence (P=0.562). The DCR of both groups were 87%and 90%, respectively, showing no significant dif erence (P=0.688). Median PFS of patients with EL and EP regimens were 5.5 months and 5 months, respectively, showing no significant dif erence (P=0.637). Adverse events were observed in al 62 patients. Grade 1 to 4 anemia was higher in the EP group than in EL group, showing significant dif erence (P=0.02). Grade 3 and 4 thrombocytopenia was seen in 4 patients (12.9%) in EL group and 1 patient (3.2%) in EP group. Although one patient had platelet transfusion owing to Grade 4 thrombocytopenia in EL group, no significant dif erence (P=0.637) were shown. The incidence of nausea/vomiting was higher in the EP group than in the EL group (96.7%vs 51.6%, P=0.00). Conclusion:The EL regimen is an ef ective and low-toxicity chemotherapy and no inferior to EP regimen in treatment response, therefore, EL regimen maybe is a good choice for patients with extensive-stage SCLC.